| Package | Version | Identity | Name/Title | Status | FMM | WG | Date | Auth |
|---|
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.109.11.1052 | Kidney Transplant | active | | | 2017-05 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.109.11.1060 | Kidney Transplant Recipient | active | | | 2019-03 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.109.11.1067 | Kidney Transplant | active | | | 2019-03 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.109.12.1012 | Kidney Transplant | active | | | 2022-03 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.109.12.1013 | Dialysis Services | active | | | 2022-03 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.109.12.1014 | ESRD Monthly Outpatient Services | active | | | 2017-05 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.109.12.1029 | Kidney Transplant Recipient | active | | | 2024-01 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.110.11.1065 | DTaP Vaccine Administered | active | | | 2021-09 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.110.11.1066 | DTaP Vaccine Administered | active | | | 2024-11 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.110.11.1068 | Hepatitis A | active | | | 2019-03 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.110.11.1070 | Hepatitis A | active | | | 2017-05 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.110.11.1078 | Measles | active | | | 2021-09 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.110.11.1080 | Measles | active | | | 2017-05 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.110.11.1085 | Measles, Mumps and Rubella (MMR) Vaccine Administered | active | | | 2017-05 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.110.11.1086 | Measles, Mumps and Rubella (MMR) Vaccine Administered | active | | | 2023-02 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.110.11.1087 | Mumps | active | | | 2023-02 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.110.11.1089 | Mumps | active | | | 2017-05 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.110.11.1098 | Rubella | active | | | 2021-02 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.110.11.110 | Rubella | active | | | 2017-05 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.110.11.1104 | Varicella Zoster | active | | | 2017-05 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.110.11.1105 | Varicella Zoster | active | | | 2025-01 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.110.11.1106 | Varicella Zoster Vaccine (VZV) Administered | active | | | 2017-05 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.110.11.1107 | Varicella Zoster Vaccine (VZV) Administered | active | | | 2023-02 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.110.11.1109 | Hepatitis A Vaccine Administered | active | | | 2017-05 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.110.11.1110 | Hepatitis A Vaccine Administered | active | | | 2024-02 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.110.11.1111 | Hepatitis B Vaccine Administered | active | | | 2021-09 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.110.11.1112 | Hepatitis B Vaccine Administered | active | | | 2023-02 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.110.11.1115 | Child Influenza Vaccine Administered | active | | | 2023-02 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.110.11.1116 | Child Influenza Vaccine Administered | active | | | 2023-02 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.110.11.1117 | Inactivated Polio Vaccine (IPV) Administered | active | | | 2021-09 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.110.11.1118 | Inactivated Polio Vaccine (IPV) Administered | active | | | 2023-02 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.110.11.1119 | Pneumococcal Conjugate Vaccine Administered | active | | | 2023-11 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.110.11.1120 | Rotavirus Vaccine (3 dose schedule) Administered | active | | | 2017-05 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.110.11.1121 | Rotavirus Vaccine (2 dose schedule) Administered | active | | | 2017-05 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.110.11.1123 | Genital Herpes | active | | | 2024-03 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.110.11.1124 | Genital Herpes | active | | | 2024-03 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.110.11.1128 | Lab Tests for Sexually Transmitted Infections | active | | | 2022-02 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.110.11.1129 | Chlamydia Screening | active | | | 2024-02 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.110.11.1133 | Pneumococcal Conjugate Vaccine Administered | active | | | 2024-11 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.110.11.1135 | HPV Test | active | | | 2024-11 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.110.11.1148 | Rotavirus Vaccine (2 Dose Schedule) Administered | active | | | 2019-03 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.110.11.1149 | Rotavirus Vaccine (3 Dose Schedule) Administered | active | | | 2019-03 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.110.11.1150 | Advanced Illness | active | | | 2025-02 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.110.11.1151 | Advanced Illness | active | | | 2025-02 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.110.11.1152 | HiB Vaccine (3 dose schedule) | active | | | 2021-12 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.110.11.1153 | HiB Vaccine (3 dose schedule) Administered | active | | | 2021-09 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.110.11.1154 | HiB Vaccine (4 dose schedule) | active | | | 2021-09 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.110.11.1155 | HiB Vaccine (4 dose schedule) Administered | active | | | 2021-09 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.110.11.1156 | HiB Vaccine (3 dose schedule) Administered | active | | | 2024-03 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.110.11.1157 | HiB Vaccine (4 dose schedule) Administered | active | | | 2024-03 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.110.11.1158 | Competing Conditions for Respiratory Conditions | active | | | 2024-02 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.110.11.1159 | Competing Conditions for Respiratory Conditions | active | | | 2023-02 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.110.12.1022 | DTaP Vaccine Administered | active | | | 2022-03 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.110.12.1024 | Hepatitis A | active | | | 2017-05 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.110.12.1031 | Measles, Mumps and Rubella (MMR) Vaccine Administered | active | | | 2022-03 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.110.12.1032 | Mumps | active | | | 2017-05 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.110.12.1037 | Rubella | active | | | 2017-05 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.110.12.1039 | Varicella Zoster | active | | | 2022-03 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.110.12.1040 | Varicella Zoster Vaccine (VZV) Administered | active | | | 2022-03 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.110.12.1041 | Hepatitis A Vaccine Administered | active | | | 2022-03 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.110.12.1042 | Hepatitis B Vaccine Administered | active | | | 2022-09 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.110.12.1044 | Child Influenza Vaccine Administered | active | | | 2022-03 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.110.12.1045 | Inactivated Polio Vaccine (IPV) Administered | active | | | 2022-03 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.110.12.1046 | Pneumococcal Conjugate Vaccine Administered | active | | | 2022-03 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.110.12.1047 | Rotavirus Vaccine (3 dose schedule) Administered | active | | | 2022-03 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.110.12.1048 | Rotavirus Vaccine (2 dose schedule) Administered | active | | | 2022-03 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.110.12.1049 | Genital Herpes | active | | | 2018-03 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.110.12.1051 | Lab Tests for Sexually Transmitted Infections | active | | | 2022-03 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.110.12.1052 | Chlamydia Screening | active | | | 2022-03 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.110.12.1053 | Measles | active | | | 2017-05 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.110.12.1059 | HPV Test | active | | | 2022-03 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.110.12.1082 | Advanced Illness | active | | | 2022-03 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.110.12.1083 | Hib Vaccine (3 dose schedule) | active | | | 2019-03 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.110.12.1084 | Hib Vaccine (3 dose schedule) Administered | active | | | 2022-03 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.110.12.1085 | Hib Vaccine (4 dose schedule) | active | | | 2019-03 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.110.12.1086 | Hib Vaccine (4 dose schedule) Administered | active | | | 2022-03 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.110.12.1087 | Influenza Virus LAIV Vaccine | active | | | 2021-02 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.110.12.1088 | Influenza Virus LAIV Vaccine Administered | active | | | 2021-02 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.111.11.1012 | Lab Tests During Pregnancy | active | | | 2023-02 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.111.11.1013 | Diagnostic Studies During Pregnancy | active | | | 2022-02 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.111.11.1019 | Pregnancy Test | active | | | 2023-02 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.111.11.1022 | Complications of Pregnancy, Childbirth and the Puerperium | active | | | 2024-02 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.111.11.1023 | Complications of Pregnancy, Childbirth and the Puerperium | active | | | 2023-02 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.111.11.1028 | Procedures for Sexual Activity | active | | | 2024-02 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.111.11.1030 | Procedures for Sexual Activity | active | | | 2024-02 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.111.11.1031 | Diagnosis for Sexual Activity | active | | | 2021-02 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.111.11.1032 | Diagnosis for Sexual Activity | active | | | 2024-02 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.111.11.1033 | Procedures for Sexual Activity | active | | | 2021-02 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.111.12.1007 | Lab Tests During Pregnancy | active | | | 2022-03 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.111.12.1008 | Diagnostic Studies During Pregnancy | active | | | 2022-03 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.111.12.1011 | Pregnancy Test | active | | | 2022-03 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.111.12.1012 | Complications of Pregnancy, Childbirth and the Puerperium | active | | | 2022-03 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.111.12.1016 | Congenital or Acquired Absence of Cervix | active | | | 2024-01 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.111.12.1017 | Procedures Used to Indicate Sexual Activity | active | | | 2022-03 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.111.12.1018 | Diagnoses Used to Indicate Sexual Activity | active | | | 2022-03 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.112.11.1024 | Absence of Cervix | active | | | 2021-02 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.112.11.1025 | Absence of Cervix | active | | | 2021-09 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.112.11.1026 | Absence of Cervix | active | | | 2023-09 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.113.11.1073 | Osteoporosis Without Current Fracture | active | | | 2017-12 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.113.11.1074 | Osteoporosis Without Current Fracture | active | | | 2023-02 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.113.11.1200 | Osteoporosis With Current Fracture | active | | | 2024-02 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.113.11.1201 | Osteoporosis With Current Fracture | active | | | 2024-02 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.113.11.1202 | DXA (Dual energy Xray Absorptiometry) Scan Non Hip or Spine | active | | | 2021-02 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.113.11.1308 | Frailty Diagnosis | active | | | 2024-11 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.113.11.1309 | Frailty Diagnosis | active | | | 2025-02 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.113.11.1310 | Frailty Symptom | active | | | 2023-02 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.113.11.1311 | Frailty Symptom | active | | | 2023-11 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.113.12.1038 | Osteoporosis Without Current Fracture | active | | | 2024-01 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.113.12.1050 | Osteoporosis With Current Fracture | active | | | 2018-03 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.113.12.1051 | DXA (Dual energy Xray Absorptiometry) Scan | active | | | 2022-03 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.113.12.1074 | Frailty Diagnosis | active | | | 2019-03 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.113.12.1075 | Frailty Symptom | active | | | 2019-03 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.114.11.1021 | Narcolepsy | active | | | 2018-08 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.114.11.1023 | Narcolepsy | active | | | 2017-05 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.114.11.1024 | Neurologic impairment | active | | | 2024-02 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.114.11.1025 | Neurologic impairment | active | | | 2017-05 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.114.11.1026 | Neurologic impairment | active | | | 2021-09 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.114.12.1011 | Narcolepsy | active | | | 2024-01 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.114.12.1012 | Neurologic impairment | active | | | 2024-02 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.1149 | Substance Use Disorder Long Acting Medication | active | | | 2024-01 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.115.11.1248 | Retinal or Dilated Eye Exam | active | | | 2025-01 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.115.12.1088 | Retinal or Dilated Eye Exam | active | | | 2022-03 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.1150 | Substance Use Disorder Short Acting Medication | active | | | 2024-01 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.1151 | Substance Use Disorder Long Acting Medication Administration | active | | | 2025-01 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.1152 | Substance Use Disorder Short Acting Medication Administration | active | | | 2024-02 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.1155 | Substance Use Disorder Short Acting Medication Administration | active | | | 2023-11 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.1156 | Substance Use Disorder Long Acting Medication Administration | active | | | 2021-11 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.1157 | Substance Use Disorder Short Acting Medication Administration | active | | | 2022-03 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.1163 | Encephalitis Due to Diphtheria, Tetanus or Pertussis Vaccine | active | | | 2022-02 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.1164 | Encephalitis Due to Diphtheria, Tetanus or Pertussis Vaccine | active | | | 2022-02 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.1165 | Hospice Diagnosis | active | | | 2022-08 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.1166 | Hospice Diagnosis | active | | | 2022-08 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.1167 | Palliative Care Diagnosis | active | | | 2022-08 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.1168 | Palliative Care Diagnosis | active | | | 2022-08 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.1169 | Palliative Care Diagnosis | active | | | 2022-08 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.117.11.1031 | Hyperthyroidism | active | | | 2018-03 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.117.11.1033 | Hyperthyroidism | active | | | 2018-03 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.117.11.1034 | Hyperparathyroidism | active | | | 2022-02 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.117.11.1036 | Hyperparathyroidism | active | | | 2018-03 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.117.12.1015 | Hyperthyroidism | active | | | 2024-01 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.117.12.1016 | Hyperparathyroidism | active | | | 2024-01 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.1170 | Atomoxetine | active | | | 2022-09 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.1171 | Clonidine | active | | | 2024-01 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.1172 | Dexmethylphenidate | active | | | 2025-01 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.1173 | Dextroamphetamine | active | | | 2022-09 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.1174 | Lisdexamfetamine | active | | | 2022-09 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.1176 | Methylphenidate | active | | | 2024-01 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.1177 | Lower Body Fractures Excluding Ankle and Foot | active | | | 2022-09 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.1178 | Lower Body Fractures Excluding Ankle and Foot | active | | | 2023-07 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.1179 | Malignant Neoplasms of Lower and Unspecified Limbs | active | | | 2022-09 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.118.11.1042 | Counseling for Physical Activity | active | | | 2019-03 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.118.11.1077 | Falls Screening | active | | | 2018-03 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.118.11.1097 | CT Colonography | active | | | 2019-03 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.118.11.1220 | Frailty Device SNOMED | active | | | 2024-02 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.118.12.1028 | Falls Screening | active | | | 2022-03 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.118.12.1035 | Counseling for Physical Activity | active | | | 2022-03 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.118.12.1300 | Frailty Device | active | | | 2022-03 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.1180 | Malignant Neoplasms of Lower and Unspecified Limbs | active | | | 2023-07 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.1181 | Mechanical Complications Excluding Upper Body | active | | | 2022-09 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.1182 | Mechanical Complications Excluding Upper Body | active | | | 2023-07 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.1183 | Partial Arthroplasty of Hip | active | | | 2022-09 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.1184 | Partial Arthroplasty of Hip | active | | | 2023-07 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.1188 | Removal, Revision and Supplement Procedures of the Lower Body and Spine | active | | | 2022-12 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.1189 | Removal, Revision and Supplement Procedures of the Lower Body and Spine | active | | | 2023-07 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.1190 | Antibiotic Medications for Upper Respiratory Infection | active | | | 2025-01 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.1193 | Malignant Neoplasms | active | | | 2022-09 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.1194 | Malignant Neoplasms | active | | | 2022-09 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.1196 | Atherosclerosis of the Extremities | active | | | 2023-07 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.1197 | Atherosclerosis of the Extremities | active | | | 2023-07 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.1198 | Atherosclerosis of the Extremities | active | | | 2023-07 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.1199 | Lower Extremity Neurological Assessment Result or Finding | active | | | 2023-07 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.120.11.1001 | Disorders of the Immune System | active | | | 2024-02 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.120.11.1003 | Disorders of the Immune System | active | | | 2024-02 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.120.11.1004 | HIV Viral Load | active | | | 2025-02 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.120.11.1008 | HIV 2 | active | | | 2023-02 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.120.11.1010 | HIV 2 | active | | | 2017-05 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.120.11.1011 | Severe Combined Immunodeficiency | active | | | 2017-05 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.120.11.1012 | Severe Combined Immunodeficiency | active | | | 2023-02 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.120.12.1001 | Disorders of the Immune System | active | | | 2022-03 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.120.12.1002 | HIV Viral Load | active | | | 2022-03 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.120.12.1003 | HIV | active | | | 2024-01 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.120.12.1007 | Severe Combined Immunodeficiency | active | | | 2022-03 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.1200 | Lower Extremity Neurological Tests | active | | | 2023-07 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.1201 | Lower Extremity Visual Inspection Result or Finding | active | | | 2023-07 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.1202 | Lower Extremity Visual Inspection Test | active | | | 2023-07 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.1203 | Monofilament Test Result or Finding | active | | | 2023-07 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.1204 | Monofilament Tests | active | | | 2023-07 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.1205 | Pedal Pulse Result or Finding | active | | | 2023-07 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.1206 | Peripheral Neuropathy | active | | | 2023-07 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.1207 | Peripheral Neuropathy | active | | | 2023-07 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.1208 | Peripheral Neuropathy | active | | | 2023-07 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.1209 | Amputation of Bilateral Feet | active | | | 2023-07 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.121.11.1011 | Consultant Report | active | | | 2022-02 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.121.11.1028 | BMI percentile | active | | | 2017-05 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.121.11.1030 | Height | active | | | 2019-03 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.121.11.1031 | Weight | active | | | 2017-05 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.121.12.1006 | Consultant Report | active | | | 2024-09 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.121.12.1012 | BMI percentile | active | | | 2022-03 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.121.12.1014 | Height | active | | | 2022-03 | hl7 |
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113883.3.464.1003.121.12.1015 | Weight | active | | | 2022-03 | hl7 |
FHIR